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Abstract
Rationale: Airways obstruction with thick, adherent mucus is
a pathophysiologic and clinical feature of muco-obstructive
respiratory diseases, including chronic obstructive pulmonary
disease, asthma, and cystic fibrosis (CF). Mucins, the dominant
biopolymer inmucus, organize into complex polymeric networks via
the formation of covalent disulfide bonds, which govern the
viscoelastic properties of the mucus gel. For decades, inhaled
N-acetylcysteine (NAC) has been used as a mucolytic to reduce mucin
disulfide bonds with little, if any, therapeutic effects. Improvement
of mucolytic therapy requires the identification of NAC deficiencies
and the development of compounds that overcome them.
Objectives: Elucidate the pharmacological limitations of NAC and
test a novel mucin-reducing agent, P3001, in preclinical settings.
Methods: The study used biochemical (e.g., Western
blotting, mass spectrometry) and biophysical assays (e.g.,
microrheology/macrorheology, spinnability, mucus velocity
measurements) to test compound efficacy and toxicity in in vitro and
in vivomodels and patient sputa.
Measurements and Main Results: Dithiothreitol and P3001
were directly compared with NAC in vitro and both exhibited
superior reducing activities. In vivo, P3001 significantly
decreased lung mucus burden in bENaC-overexpressing mice,
whereas NAC did not (n = 6–24 mice per group). In NAC-treated
CF subjects (n = 5), aerosolized NAC was rapidly cleared from
the lungs and did not alter sputum biophysical properties. In
contrast, P3001 acted faster and at lower concentrations than
did NAC, and it was more effective than DNase in CF sputum
ex vivo.
Conclusions: These results suggest that reducing the viscoelasticity
of airway mucus is an achievable therapeutic goal with P3001 class
mucolytic agents.
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In healthy individuals, mucus is secreted
by airway epithelial cells and submucosal
glands to trap and clear inhaled particles
from the lung. The biophysical properties of
airway mucus are governed by the secreted
polymeric mucins, MUC5AC and MUC5B,
which are high-molecular-mass
glycoproteins that organize into large
multimers (2–100 MDa) via the formation
of intermolecular disulfide bonds. In
muco-obstructive diseases, including
chronic bronchitis, asthma, and cystic
fibrosis (CF), mucin hypersecretion,
hyperconcentration, and increased mucin
cross-linking slow mucus transport,
producing persistent mucus plugging
and airflow obstruction (1–3). Adding
complexity to the pathophysiology of these
diseases, recent studies suggest that the
properties of MUC5AC and MUC5B differ
and each mucin may be dominant in
different muco-obstructive diseases; for
example, MUC5AC dominates in asthma
and MUC5B dominates in chronic
obstructive pulmonary disease (COPD) and
CF (4, 5).
For decades, mucolytic agents have
been pursued as a therapeutic approach to
treat muco-obstructive diseases. Reducing
agents that disrupt the mucin
intermolecular covalent disulfide bonds are
predicted to disadhese mucus from airway
surfaces and improve clearance. Mucomyst
(N-acetylcysteine [NAC]) was approved as
an inhaled therapy for patients with CF and
chronic bronchitis in the 1960s. However,
clinical data in CF and COPD do not
support the efficacy of inhaled NAC with
respect to improvement of lung function or
reduction in pulmonary exacerbations
(6–9). These negative clinical NAC studies
have limited the enthusiasm for inhaled
mucolytics as therapeutic options for
muco-obstructive lung diseases. In contrast,
recombinant human DNase (rhDNase or
dornase alfa), an enzyme that breaks down
the extracellular DNA released by dying
neutrophils entrapped in the mucus,
produced substantial clinical benefits in
adult CF subjects (10–12). These positive
results validated the concept that an inhaled
drug that affects the rheology of airway
secretions could improve health outcomes.
However, rhDNase is only active in CF
subjects with persistent inflammation and
was ineffective in obstructive diseases other
than CF (13–15). Recently, reducing agents
have been reported to produce greater
effects on CF sputum viscoelasticity than
rhDNase in vitro (1, 16), suggesting they
may benefit CF subjects and a broader
population.
Our study was designed to elucidate
the mechanisms underlying the clinical
failure of NAC as an inhaled mucolytic and
test whether novel candidates could
overcome these deficiencies. Accordingly,
NAC reducing activity was compared
with dithiothreitol (DTT) and a novel
mucolytic agent, P3001, in human
bronchial epithelial (HBE) cell mucus,
COPD patient sputa, and mouse BAL fluid
(BALf). Mucolytic activities were tested in a
series of biochemical and biophysical
assays, including mucin agarose gel,
macrorheology and microrheology, and
mucus transport rates assays. The
efficacy of P3001 was tested in wild-type
(WT) and bENaC-overexpressing
mice, an in vivo model of chronic
muco-obstructive lung disease. Finally, we
measured the pharmacokinetics and
pharmacodynamics of NAC after a single
administration of inhaled 20% NAC in
CF subjects and compared P3001 effects to
NAC and rhDNase in sputum obtained
from these subjects. Some of these results
have been previously reported in abstracts
(17, 18).
Methods
For detailed information on laboratory and
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Figure 1. The reduction potential of P3001 exceeds that of dithiothreitol and N-acetylcysteine.
Spectrophotometric studies monitored formation of reduced 59,59-dithio-bis(2-nitrobenzoic acid)
over time. Reaction rates, generated using second-order kinetics, for each compound were
compared as a (A) function of reducing agent concentration at pH 6.5 or (B) over a relevant pH range.
The x-axis reflects the pseudo–second-order kinetics of the reducing reaction rates per molar per
second. DTT = dithiothreitol; NAC =N-acetylcysteine.
At a Glance Commentary
Scientific Knowledge on the
Subject: Inhaled mucolytic agents are
designed to decrease the viscoelasticity
of airway secretions, improve
mucociliary clearance, and reduce the
mucus burden in the lungs of patients
suffering from muco-obstructive
pulmonary diseases. Reducing agents
break the disulfide bonds that connect
mucin macromolecules by donating
electrons to the thiol groups of mucin
monomer cysteine residues, changing
the rheology of mucin-rich secretions.
What This Study Adds to the
Field: This study identified
the deficiencies of the only
approved inhaled reducing agent,
N-acetylcysteine (NAC), and
compared NAC with novel reducing
agents. As observed in in vitro and
in vivo studies, the low intrinsic
reducing activity and short half-life
of NAC on airway surfaces are
responsible for its ineffectiveness.
Next-generation reducing agents
tested in preclinical assays exhibited
significant improvements in reducing
activity, restoration of mucus
transport, and reduction of lung
mucus burden in mouse models. This
study supports the need for novel
reducing agents and provides unique
insights into new mucolytic agents as
inhaled therapies to treat lung disease.
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Biological Specimens
COPD and CF sputa were spontaneously
expectorated and processed for biophysical
and biochemical measurements. HBE
airway epithelial cells were grown at an
air–liquid interface and washed weekly
to provide mucus samples. Procedures
involving human cells and sputum
specimens were approved by the
Institutional Review Board (approval nos.
03-1396, 12-2602, and 02-0948) at the
University of North Carolina Chapel Hill.
WT and bENaC-overexpressing mice
were used to test efficacy and/or toxicity of
pharmacological compounds via Western
blotting, mass spectrometry, cell counts,
and morphometric measurements. Animal
use was approved by the University of
North Carolina Chapel Hill Institutional
Animal Care and Use Committee.
Experimental Procedures
The biochemical methods included a
colorimetric assay using an artificial S–S
target (59,59-dithio-bis[2-nitrobenzoic acid]
[DTNB]) substrate to characterize intrinsic
and pH-dependent reductive activities of
test molecules. Agarose gel electrophoreses
and Western blotting measured the
molecular mass of mucins in sputum,
HBE secretions, and BALf from mice.
Immunohistochemical methods were
employed to characterize the mucin
structure in COPD sputum. Measurements
of NAC and NAC metabolite concentration
in CF sputum were performed by mass
spectroscopy.
The biophysical measurements of
mucus properties included 1) a capillary
break assay using an extension rheometer,
2) microbead rheology, and 3)
macrorheology using a parallel plate
oscillating rheometer.
Mice were dosed with test compounds
via nasal instillation (15 ml) or via a
modified ultrasonic aerosol generator
designed to deliver z1 ml transnasally to
mouse lower airways. BAL was used to
sample mucins and deposited drug from
mouse lungs. Morphometry was used to
measure lung mucus burden.
Statistics
The effects of varying concentrations of
agents were analyzed by a two-way ANOVA
Dunnett test for multiple comparisons.
Independent sample groups were analyzed
by a Mann-Whitney U test. All tests are
two-sided, and significance level is 0.05. All
results are reported in terms of means6
SEM.
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Figure 2. Effect of N-acetylcysteine (NAC), dithiothreitol (DTT), and a novel reducing agent, P3001, on the biochemical and biophysical properties of
chronic obstructive pulmonary disease sputum. Freshly harvested sputa were aliquoted and subjected to increasing concentrations (0.01–10 mM) of NAC,
DTT, or P3001 at 378C for 30 minutes and then quenched. (A) Electrophoretic separation reveals the biochemical effect of each compound on mucin
multimerization. MUC5AC and MUC5B signals are shown individually or as an overlay (red indicates MUC5AC; green indicates MUC5B). (B) Graph
indicates the degree of mucin reduction as percentage of monomeric signal intensity (e.g., full or 100% MUC5B reduction was achieved at 10 mM DTT).
(C) Graph reveals changes in sputum biophysical properties as measured by spinnability, also referred to as capillary break. n = 6 for NAC and P3001 and
n = 4 for DTT. **P, 0.01, ***P, 0.0001, ****P, 0.00001, two-way ANOVA Dunnett test. LMW= low molecular weight.
ORIGINAL ARTICLE
Ehre, Rushton, Wang, et al.: Preclinical Study of Inhaled Reducing Agents 173
 
Results
Comparing Reducing Activity of NAC
with Other Reducing Agents
NAC was compared with two alternative
reducing agents, DTT and the novel
mucolytic agent P3001. DTT is a well-
characterized (12), rapidly acting reducing
agent. P3001 is predicted to be more
effective than NAC based on a lower pKa of
the active moiety (7.6) and more rapid
kinetics of disulfide bond reduction. An
artificial substrate (DTNB) was used to
directly measure the kinetics of interaction
between each candidate and its substrate,
that is, DTNB S–S bond (Figure 1). As
reported, NAC exhibited slow, pH-
dependent reaction rates. DTT reaction
rates were z10-fold faster than NAC and,
again, pH dependent. P3001 exhibited an
additional 10-fold pH-dependent increase
in reaction rates over DTT, producing an
increase in activity of z100-fold over NAC.
Thus, NAC, DTT, and P3001 exhibit a
spectrum of reductive activities suitable for
testing in mucus environments.
Note that DTT is not considered
as a clinical candidate because low
concentrations of DTT permeate into cells,
induce endoplasmic reticulum stress, and
enhance H2O2-induced toxicity (19). In
contrast to DTT or NAC, P3001 is odorless
and only allows limited cellular uptake due to
its size, polar surface, and hydrophilicity.
Consistent with absence of cell permeation,
HBE cultures exposed to P3001 (2 mM) via
nebulization twice daily for 2 weeks did not
exhibit cell stress as indexed by XBP1 splicing
and/or cytokine assays and had no off-target
effects on mucin expression or production
(see Figure E1 in the online supplement).
The reducing activities of the three
compounds were next compared in COPD
sputa via mucin agarose electrophoresis and
spinnability (capillary break) assays. Three
COPD specimens, selected for homogeneity,
similar concentrations (5–8% solids), and
low salivary and inflammatory cell content
(limiting proteolytic activity), were exposed
to increasing concentrations of NAC, DTT,
or P3001 (0–10 mM for 30 min). Note
that deposition models predict that 20%
(1.27 M) NAC delivered by a conventional
nebulizer does not exceed 10 mM on
distal airway surfaces and will be cleared
within 30 minutes (see Figure E2). The
dose–response curves for DTT or P3001
versus low-molecular-weight (LMW)
MUC5B production were significantly left-
shifted compared with NAC (Figures 2B
and E3). Spinnability measurements also
showed that the dose–effect relationships
for DTT or P3001 were significantly left-
shifted compared with NAC (Figure 2C).
Importantly, full mucin reduction by DTT
or P3001 was not required to change mucus
biophysical properties. At the lowest
concentration tested (0.01 mM), DTT and
P3001 generated only 19% and 7% LMW
MUC5B production, respectively, which
correlated with an z50% decrease in
spinnability for both compounds. In
0.2 0.5 201 2
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Figure 3. Alterations of the mucin network following treatment of chronic obstructive pulmonary
disease sputum. The same patient sputum was treated with N-acetylcysteine (NAC) or P3001 for
30 minutes at 378C and analyzed to compare the structural changes of the mucin network. (A)
Breakdown of multimeric MUC5B was assessed by agarose gel electrophoresis. Increasing
concentration of NAC (0.2–200 mM) and P3001 (0.2–20 mM) were tested. (B) Effect of 20 mM NAC
and P3001 on sputum elastic modulus (G9) as measured by a cone-and-plate rheometer and
compared with PBS. **P, 0.01. n = 3 repeats per condition. (C) Effect of 20 mM NAC and P3001 on
the mucin network topology as examined by immunocytochemistry and compared with PBS.
Confocal images captured the disruption of MUC5AC (red) and MUC5B (green) threads as a result of
sputum reduction. Nuclei are shown in blue (DAPI). Scale bar, 100 mm. PBS = phosphate-buffered
saline.
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contrast, 10 mM concentrations of NAC
were required to produce a 20% LMW
MUC5B production and a 24% decrease in
spinnability within 30 minutes, consistent
with slower reduction of intermolecular
disulfide bonds by NAC. The observation
that DTT and P3001 exhibited similar
dose–effect relationships for MUC5B
reduction and spinnability, juxtaposed to
the 10-fold faster DTNB reduction kinetics
of P3001 versus DTT, suggests that P3001
has more limited access to mucin S–S
bonds than does DTT.
Because impaired mucus strand
detachment was shown to disrupt
mucociliary clearance in CF models (20), we
tested the effects of P3001 on submucosal
gland mucus. Western blotting revealed
that P3001 was at least 10-fold more potent
than NAC at breaking down submucosal
gland mucus, and scanning electron
microscopy images established that P3001
disrupted methacholine-stimulated mucus
strands (Figure E4).
Physical Alterations of the Mucin
Network in Response to Reducing
Agents
To measure the effects of mucin reduction
on macroscopic mucus properties, COPD
sputum was exposed to increasing
concentrations of NAC (0.2–200 mM) or
P3001 (0.2–20 mM) and analyzed by
agarose mucin gel, immunostaining, and
cone-and-plate rheometry. Western
blotting confirmed that treatment with
20 mM P3001 caused full reduction of
MUC5B, whereas 20 mM NAC produced
partial reduction (Figure 3A). The marked
changes in the migration pattern of sputum
exposed to 20 mM P3001 correlated with
anz10-fold decrease in the elastic modulus
(Figure 3B). In comparison, NAC at the
same concentration had a negligible impact
on sputum biophysical properties. The
electrophoretic and biophysical responses
to NAC versus P3001 were paralleled by the
immunochemical characterizations of
mucin network topologies that showed
relaxation of interwoven structures with
P3001 (Figure 3C).
In Vitro Effect of NAC and P3001 on
Mucus Transport
HBE cells grown at an air–liquid interface
coordinate ciliary beating and organize
mucus transport in a rotational fashion
(i.e., “mucus hurricanes”). To mimic
patient dosing and maintain HBE surfaces
under thin-film conditions, HBE cultures
were exposed to aerosols generated by
an eFlow nebulizer modified to deposit
3 ml/cm2 phosphate-buffered saline (PBS;
with/without drugs) during 10 seconds,
which contained fluorescent beads for
tracking. Non–CF cells maintained
transport throughout the 2-hour post-PBS
nebulization period, whereas, as previously
reported, mucus transport ceased 2 hours
after PBS nebulization for CF cultures (21,
22). CF cultures exposed to NAC (5 mM
nebulized) exhibited modestly increased
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Figure 4. Effect of N-acetylcysteine and P3001 on cystic fibrosis (CF) human bronchial epithelial mucus transport. Human bronchial epithelial cells grown
on air–liquid interface typically coordinate cilia beating and transport secreted material in a rotational manner (e.g., mucus hurricane). Mucus transport or
velocity was tracked using fluorescently labeled microbeads (1 mm) while cells were maintained under thin-film conditions. (A) Long-exposure images of
non-CF and CF cells nebulized with PBS (3 ml/cm2). Additionally, the same CF cells were nebulized with P3001 (5 mM). After P3001 treatment, beads
cleared away from the initial anchor point (e.g., disruption of the mucus aggregate) but maintained the same overall directionality (e.g., clockwise rotational
movement). Mucus transport was monitored for 2 hours. (B) Graphs show mucus velocity of non-CF and CF cells treated with PBS (i) or CF cells treated
with 5 mM N-acetylcysteine or P3001 (ii). n = 3. *P, 0.05, **P, 0.01. NAC =N-acetylcysteine; PBS = phosphate-buffered saline.
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waned by 2 hours. In contrast, P3001
(5 mM nebulized) induced a large and
sustained increase in CF cultures mucus
velocity that persisted for 2 hours and
was z10-fold on average above CF cells
exposed to PBS (Figure 4).
In Vitro Effect of NAC and P3001 on
Murine Muc5b in BALf
Prior to in vivo testing, NAC and P3001
effectiveness were assessed on mucins
harvested by BAL from WT and bENaC-
transgenic (Tg) mice. Muc5b, the dominant
mucin expressed in murine lungs, is
about fourfold more concentrated in
bENaC-transgenic (Tg) than in WT BALf.
Because both mucolytic agents exhibit a
stoichiometry of one molecule per one
disulfide bond, it is important for therapy
of lung diseases with increased mucin
concentrations to control for drug/target
stoichiometry in dose–response
experiments. Dose–effect studies of NAC
and P3001 (0.02–20 mM) in WT mouse
BALf (Figure 5) revealed that P3001
produced dose-dependent Muc5b reduction
whereas NAC did not. Similar relationships
were observed for NAC and P3001 in
bENaC mouse BALf. However, a modest
rightward shift was noted when comparing
P3001 in WT versus bENaC BALf, for
example, 2 mM P3001 generated 43%
LMW Muc5b in WT mice compared with
z24% LMW Muc5b in bENaC BALf,
reflecting increased bENaC mucin
concentration. Accordingly, the mass of a
reducing agent delivered to patients will
need to be adjusted according to the
pulmonary mucus burden.
In Vivo Effect of NAC and P3001 on
WT Mice
WT mice were treated via intratracheal
instillation (15 ml) of NAC at a
concentration mimicking clinical doses,
for example, 10% or z600 mM, or
concentrations of P3001 z50-fold lower
than NAC that produced significant mucin
reduction in in vitro assays, that is, 12 mM.
No reduction of Muc5b after NAC delivery
was detected by Western blotting during a
1-hour period (Figure 6A). In contrast,
P3001 produced full reduction of Muc5b
within 15 minutes after treatment.
Interestingly, reduced mucins were cleared
from the lungs with time and replaced by
newly synthetized, intact polymeric mucins
during 60 minutes (Figure 6A).
Investigations into the failure of NAC
to reduce Muc5b in vivo revealed that NAC
was rapidly cleared/absorbed from murine
lungs; that is,z70% of the drug was cleared
within 15 minutes and little was detected
in BALf 60 minutes after administration
(Figure 6B). Analyses of BALf for NAC
toxicity revealed an increase in total cell
number (Figure 6C), neutrophils, and
histologic evidence of epithelial injury, for
example, appearance of eosin-positive
crystals (Figure 6D), suggesting that the
inefficiency of NAC could not be overcome
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Figure 5. In vitro testing of N-acetylcysteine (NAC) and P3001 potency on mouse BAL fluid. BAL fluid from wild-type (WT) and bENaC-transgenic mice
were subjected to increasing concentration of NAC and P3001 (0.02–20 mM). Samples were incubated at 378C for 15 minutes and then quenched.
(A) Western blotting was used to assess NAC and P3001 potency at different concentrations and at different stoichiometric ratios because mucin
concentration was increased fourfold in bENaC mice as compared with WT animals. (B) Reduction of high-molecular-weight multimer intensity that
reflects partial of full Muc5b reduction is graphed for NAC (gray circles) and P3001 (black squares) in the two models. NT = no treatment.
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exposed to lower doses of P3001 showed no
signs of inflammation or epithelial damage
(Figures 6C and 6D).
In Vivo Effects of Aerosolized Agents
in bENaC-Tg Mice
bENaC-Tg mice were exposed via a nose-
only nebulizer to small volumes (z1 ml
deposited) of normal saline (NS), NAC, or
P3001 during a 15-minute interval. Equal
drug concentrations (200 mM) were placed
in the aerosol generator. Mass spectrometry
of BALf collected immediately after
inhalation confirmed that 1.5 mg/kg
(z12 mM) of P3001 was deposited into
the lungs using this technique.
Morphometric analysis of AB/PAS
histological sections revealed a robust
mucus burden in sham-treated bENaC-Tg
mice (Figure 7). Hydration via normal
saline aerosolization produced an overall
reduction in the AB/PAS mucus burden, as
reported previously (23, 24). NS-treated
mice showed a trend toward bimodal
distribution. Hence, the number of
animals was increased to demonstrate
that some mice (30%) responded to NS
administration and others did not (Figure
E5), suggesting that more tenacious plugs
require a mucolytic drug for removal.
The NAC-exposed group was not different
from the sham group (Figure 7B). However,
the P3001-exposed group exhibited
significantly reduced airway mucus
obstruction compared with sham-treated





To test the hypothesis that delivered mass
and residency time of NAC were inadequate
for mucin reduction, spontaneous sputa
were collected from five CF adult subjects at
baseline and at 15 minutes and 90 minutes
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Figure 6. Comparing N-acetylcysteine (NAC) and P3001 efficacy and toxicity in wild-type mice. Wild-type mice were treated via oropharyngeal aspiration
(15 ml) with NAC at 50 mg/kg or P3001 at 1.5 mg/kg. BAL fluid was collected at various time points (15, 30, 45, and 60 min and 6 h). (A) NAC and
P3001 efficacy to reduce Muc5b in vivo was assessed by agarose gel electrophoresis during a 60-minute period. (B) NAC pharmacokinetic properties in
the murine lungs were established by measuring NAC concentrations in BAL fluid via mass spectrometry. n= 3–5 animals per time point. (C) Inflammatory
responses were measured 6 hours after treatment and are displayed as total cell count (i) and percentage neutrophils (ii). n = 4–6 mice per group.
*P, 0.05, **P, 0.01. (D) Representative images of hematoxylin and eosin–stained sections of mouse lungs harvested 30 minutes after treatment
with NAC and P3001. Veh = vehicle.
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measurements of NAC and the reduced
N,N9-diacetyl-L-cystine metabolite revealed
peaks 15 minutes after aerosolization of 37
and 50 mM, respectively, suggesting that of
the total deposited NAC (z100 mM) only
half had reacted with S–S bonds at t = 15
min (Figure 8A). Concentrations of NAC
were not detectable 90 minutes after
administration, and NAC/N,N9-diacetyl-L-
cystine fell to z25% of its 15-minute
concentration.
As shown in Figure 8B, passive bead
diffusion measurements revealed no
detectable increase in mean square
displacement (MSD; a correlate of
viscoelastic properties) in CF sputum
following NAC inhalation. This result was
consistent with Western blot analyses of
sputum samples (Figure E6). In contrast,
NAC (100 mM) administration to sputa
ex vivo for 90 minutes, to mimic the total
NAC exposure/concentration in vivo,
produced an increase in MSD and
increased MUC5B mobility on Western
blots (Figures 8B and E6). These data
demonstrate that NAC could be an effective
mucolytic if it remained longer on the
airways, acted faster, and/or was present in
higher concentrations.
In comparison, P3001 produced a
significant increase in MSD following
incubation at 10-fold lower concentrations
(10 mM) than NAC over a 6-fold shorter
period (15 min) (Figure 8C). Importantly,
the P3001 effect on microrheology was
significantly greater than rhDNase at 15
minutes. Therefore, P3001 is predicted to
act faster and at low enough concentrations
to be clinically effective.
Discussion
In pulmonary medicine, there has been
a long-standing need to treat diseases
associated with mucus accumulation in the
lungs. The overarching goal of an inhaled
therapy is to clear the hyperconcentrated,
adherent mucus that causes airflow
obstruction, inflammation, and infection.
Reducing the molecular mass of mucin gel
polymers is a straightforward approach to
treat a broad spectrum of muco-obstructive
diseases and was tested several decades ago
with NAC. Studies from the 1960s suggest
that high concentrations of NAC could































Figure 7. Comparing N-acetylcysteine (NAC) and P3001 efficacy to remove persistent mucus plugs
from bENaC-overexpressing mice by aerosolization. bENaC-overexpressing mice were slightly
anesthetized with isoflurane and subjected to repeated 15-minute nebulizations (nose only, three
times, 2-h intervals) with normal saline, NAC, or P3001 at 200 mM. Lung sections were stained
with alcian blue–periodic acid/Schiff (AB-PAS) and morphometric analysis was performed. (A)
Representative images of AB-PAS sections of animals exposed to sham (n = 9) or treated with saline
(n = 24), NAC (n = 6), and P3001 (n = 6). Images display the proximal region of the left main stem
bronchus, a site routinely presenting significant mucus obstruction in bENaC-transgenic animals.
Scale bar, 100 mm. (B) Morphometric measurement of AB-PAS–positive signal in whole-lung


































































Figure 8. N-acetylcysteine (NAC) pharmacokinetics and mucolytic effects on cystic fibrosis (CF) sputum measured by microrheology. Five individuals with
CF were treated with 20% (1.27 M) NAC via inhalation. Spontaneously expectorated sputa were collected 0, 15, and 90 minutes after treatment. (A)
Sputum drug concentrations measured using mass spectrometry at 0, 15, and 90 minutes. (B) Sputum microrheology or mean square displacement
(MSD) measured at baseline and 90 minutes after NAC treatment (in vivo) by tracking 1-mm fluorescence beads mixed in sputum specimens. In parallel,
aliquots of sputa collected at baseline were incubated at 378C with 100 mM NAC for 90 minutes (ex vivo). (C) MSD of baseline sputa incubated ex vivo at
378C with 0.1 mg/ml rhDNase or 10 mM P3001 for 15 minutes. Passive bead diffusion (or MSD) is shown as scatter plot of MSDt=0.83s for tracer particles
in sputum for each treatment condition. *P, 0.05. BSL = baseline; DiNAC=N,N9-diacetyl-L-cystine.
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tracheostomies when delivered topically
via bronchoscopy (25–28). Studies from
the early 1970s described modest
improvements in lung function following
inhalation NAC treatment, which may
have reflected the osmotic activity of the
high NAC concentrations (20%, 1,200
mOsm) aerosolized. Indeed, human
studies (29, 30) showed that the effects
of NAC on mucociliary clearance were
mimicked by equiosmotic concentrations
of NaCl. Our studies in WT mice
paralleled these findings, demonstrating
that delivery of high concentrations of
NAC induced epithelial cell damage and
acute neutrophilic responses that may in
part have reflected the large osmotic load
deposited (Figure 6). The limited efficacy
of NAC, coupled with the off-target
irritation effects, including cough and
bronchospasm, appear responsible for its
failure in clinical pulmonary medicine as
an inhaled mucolytic (6–9).
Our studies were designed to elucidate
the mechanisms for the clinical failure of
NAC and test whether a novel molecule in
the thiol-reducing class could overcome
these deficiencies. Small-molecule reducing
agents reduce protein disulfide bonds via
a stoichiometric bimolecular chemical
reaction. The speed of the reaction is directly
dependent on their intrinsic activity and
access to the target S–S bonds. The efficacy
of reduction is also dependent on the
residence time on airway surfaces of a given
agent. As indicated by the DTNB studies,
NAC has a low intrinsic reducing activity
(Figure 1). This deficiency is compounded
by the alkaline pKa of its thiol group
(z9.5). The thiolate anion form (S2) of the
NAC sulfur is required for attack on mucin
S–S bonds. On a normal airway surface
with a pH of z7.0–7.2, NAC is then 99% in
the inactive protonated form. Although
NAC will cycle from SH (inactive) to S2
(active) forms over time in airway mucus,
this process is slow and requires NAC to be
retained on the airway surfaces for long
time periods to react to completion
(Figures 8 and E6). However, NAC is
rapidly cleared and/or absorbed from
epithelial surfaces (Figures 6B, 8A, and
E2) and, consequently, not present at
sufficient concentrations or durations to
be efficacious in human airways. Consistent
with these analyses, NAC administered at
maximum tolerated doses (20%) did not
produce mucus reduction in CF subjects
(Figures 8 and E6).
The paucity of mucolytic drugs
in development relates to the fact that
the mechanisms mediating mucus
accumulation in the lungs have remained
elusive. However, a recent polymer physics
formulation has emphasized the interplay
between the cell surface–tethered mucins,
the secreted mucins within the mucus
layer, and mucus transport. The two-gel
model, which emphasizes the importance
of mucus layer concentration in
determining transport versus failure to
transport from the lung (2), has provided a
framework for understanding the role of
mucus-hydrating agents (e.g., inhaled
hypertonic saline, ion transport
modulators) to restore mucus transport.
Previous predictions and recent data have
also suggested that intermucin disulfide
bonds can be formed under conditions of
inflammation and oxidant stress (1, 3).
Such bonds would be predicted to limit
hydration-induced swelling and clearance,
providing a rationale for mucin-targeted
mucolytic agents.
NAC chemical profiling suggests that
properties of novel mucolytic molecules
should include: 1) high efficiency/rates of
disulfide reduction and/or 2) prolonged
residence times on airway surfaces. P3001
is both more intrinsically active than NAC
and exhibits significant activity at pH 7
(Figure 1). The increased activity was
reflected in P3001 being more effective
than NAC in reducing mucins in vitro
(Figures 2–5 and E3). Note that P3001
reduced MUC5AC and MUC5B equally
well, suggesting that P3001 may have
activity against mucus accumulation in
a broad range of respiratory diseases.
Similarly, the increased activity of P3001
was reflected in studies of in vivo mucin
reduction in WT mice (Figure 6).
Importantly, these in vivo effects were
achieved without evidence in vitro or
in vivo of P3001 toxicity.
Three approaches were used to test
the therapeutic utility of P3001 in
muco-obstructive diseases. First, the CF
mucus transport studies demonstrated
restoration of mucus clearance with P3001
but not NAC administration (Figures 4
and 7). Note that these experiments were
performed with compounds nebulized in a
PBS/NS solution; hence, they may reflect
the effect of the mucolytic agent plus
hydration. Reducing agents formulated as
dry powder would test whether mucolytic
therapies alone are active. Second, the
studies of inhaled NAC versus P3001 in
bENaC-Tg mice provided in vivo evidence
that an effective mucolytic agent could
reduce the mucus burden in mice with
muco-obstructive lung disease. Strikingly,
clearance of mucus plugs was observed
with three administrations of P3001 in
a single day (Figure 7). Third, P3001
was more effective in reducing viscosity
than a clinically relevant concentration
of DNase in CF sputum in vitro
(Figure 8C).
A key consideration in developing
novel mucolytics for human subjects with
muco-obstructive diseases is outcome
measures. Relief from symptoms and
improvement in airflow will be pivotal.
However, biomarkers may be important
in early studies searching for activity and
dose optimization. Biochemical assays, for
example, Western blotting, directly measure
the biochemical activity of this class of
mucolytics. However, the goal of therapy is
to improve the biophysical properties of
mucus that relate to transportability. A
variety of biophysical assays are available
and applicable to sputum samples, including
microbead/macrorheology and spinnability.
Interestingly, the spinnability assay revealed
more profound effects of reducing agents on
mucus than did Western blots (Figure 2).
Thus, it will be important in clinical early
development programs to compare
biochemical and biophysical measures of
mucus with outcomes of clinical benefit.
In summary, our analyses of NAC
suggested that its failure reflected low
intrinsic activity and limited residence time
on airway surfaces. Improving these
properties, as exemplified in P3001,
demonstrated that reducing viscoelasticity
of airway mucus with mucolytic agents may
be an achievable therapeutic goal. Targeted
treatment of pathologic airway mucus in
the future may improve symptoms of cough
and dyspnea, decrease the frequency of
disease-related exacerbations, and slow
disease progression in a broad range of
muco-obstructive diseases. n
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